

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-98)

Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</p> <p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>		<p align="center">Complete if Known</p>	
		Application Number	Continuation of 09/833,855
		Filing Date	September 17, 2003
		First Named Inventor	Xue-Feng Pei
		Group Art Unit	
		Examiner Name	
Sheet	1	of	2
		Attorney Docket Number	SYM 112 CON

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/ISB/08A (10-06)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Continuation of 09/833,855
Filing Date	September 17, 2003				
First Named Inventor	Xue-Feng Pei				
Group Art Unit					
Examiner Name					
Sheet 2 of 2	Attorney Docket Number	SYM 112 CON			

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Advanced Organic Chemistry, 4 th ed., Wiley-Interscience Publication, New York (1992).	
FB		CHEN, et al., "Evaluation of five methods for testing anticonvulsant activities," <i>Proc. Soc. Exp. Biol. Med.</i> 87: 334-339 (1954).	
FB		HUSSY, et al., "Functional properties of a cloned 5-hydroxytryptamine ionotropic receptor subunit: comparison with native mouse receptors," <i>J. Physiol. (Lond.)</i> 481(2): 311-323 (1994).	
FB		LE PEILLET, et al., "The non-NMDA antagonists, NBOX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat," <i>Brain Res.</i> 571: 115-120 (1992).	
FB		LIPTON & ROSENBERG, "Excitatory amino acids as a final common pathway for neurologic disorders," <i>N. Engl. J. Med.</i> 330: 613-622 (1994).	
FB		MCBURNEY, "Therapeutic potential of NMDA antagonists in neurodegenerative diseases," <i>Neurobiol. Aging</i> 15: 271-273 (1994).	
FB		MELDRUM, "Excitatory amino acids in epilepsy and potential novel therapies," <i>Epilepsy Res.</i> 12: 189-196 (1992).	
FB		Remington's Pharmaceutical Sciences, 17 th ed., p. 1418 (1985).	
FB		SMITH & MELDRUM, "Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat," <i>Stroke</i> 23: 861-864 (1992).	
FB		TARNAWA, et al., "Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GYKI 52466," <i>Eur. J. Pharmacol.</i> 167: 193-199 (1989).	
FB		YAMAGUCHI, et al., "Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBOX in maximal electroshock and chemoconvulsant seizure models," <i>Epilepsy Res.</i> 15: 179-184 (1993).	

Examiner's Signature	<i>EBenkurst</i>	Date Considered	3/19/04
----------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+